Summary of Study ST001215
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000811. The data can be accessed directly via it's Project DOI: 10.21228/M8VD62 This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
| Study ID | ST001215 |
| Study Title | Effect of Mirabegron Treatment on serum lipidome |
| Study Summary | Determine the lipidome changes in the serum of human subjects treated with a single dosage (200mg) of the beta-3 adrenoceptor agonist Mirabegron. |
| Institute | Joslin Diabetes Center |
| Last Name | Leiria |
| First Name | Luiz |
| Address | One Joslin Place, 02215, Boston, MA-USA |
| luiz.leiria@joslin.harvard.edu | |
| Phone | 617-309-1967 |
| Submit Date | 2016-10-23 |
| Raw Data Available | Yes |
| Raw Data File Type(s) | wiff |
| Analysis Type Detail | LC-MS |
| Release Date | 2019-09-23 |
| Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Collection:
| Collection ID: | CO001276 |
| Collection Summary: | Human plasma was acquired from a previously performed clinical trial (Cypess et al., 2015) registered with ClinicalTrials.gov (NCT01783470) and had the FDA Investigational New Drug (IND) registration number 116246. It was approved by the Human Studies Institutional Review Boards of Beth Israel Deaconess Medical Center (BIDMC) and Joslin Diabetes Center (JDC). Blood samples were collected 180 minutes after oral dosing. 180 minutes is the corresponding T max (time after administration of a drug when the maximum plasma concentration is reached) found for mirabegron in men (Baskin et al., Diabetes 2018). |
| Sample Type: | Blood (plasma) |
